Navigation Links
Curemark Announces Four New Sites Participating in Autism Study
Date:12/2/2010

RYE, N.Y., Dec. 2, 2010 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that four additional sites across the country are now participating in Phase III clinical trials for the company's autism treatment CM-AT.  The new trial sites are:

  • Institute for Behavioral Medicine, Smyrna, Georgia
  • Cyn3rgy Research, Gresham, Oregon
  • Westside Medical Clinic, Clinton, Utah
  • Oklahoma University Physician's Child Study Center, Oklahoma City

There are now a total of 19 sites nationally conducting Phase III trials for Curemark's autism therapy.  The study is targeting a total enrollment of 170 children.

"We have been extremely pleased with the response and the level of participation in the CM-AT autism study," said Dr. Joan Fallon, Curemark founder and CEO.  "Enrollment is continuing to proceed well at our other trial sites throughout the country."

CM-AT, which has received Fast Track status from the FDA, targets enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the availability of amino acids, the building blocks of chemicals essential for brain function.  If approved, CM-AT will be one of the first therapies to address the underlying physiology of autism.  

For information on enrolling in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant
2. Curemark Moderates Autism Panel at Life Sciences Summit 2010
3. Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference
4. James F. Szigethy Named Curemarks Director of New Product Development
5. Curemark to Present at BioPharm America™ 2010
6. Curemark to Present at the Rodman & Renshaw Annual Global Investment Conference
7. Curemark Opens Autism Trials at New Jersey Site
8. Curemark Begins Autism Trials at Two More Sites
9. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
10. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
11. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
Breaking Medicine News(10 mins):